NCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
Karyopharm Therapeutics Inc
Hoosier Cancer Research Network
Celgene
University of California, San Diego
Piedmont Cancer Institute
Medical College of Wisconsin
M.D. Anderson Cancer Center
Radiation Therapy Oncology Group